Cube Dx hybcell technology


Contact information



We do not assume any responsibility for the content of our homepage. Any information provided by this homepage is of general nature. It does not replace commercial, medical or other consulting. For any damages, injuries or losses due to the use of this information, no responsibility is assumed. Hyperlinks on this homepage do not state any recommendation by Cube Dx. No responsibility for content of the hyperlinks is assumed.


Legal information:

Cube Dx GmbH
A-4300 St. Valentin, Westbahnstrasse 55
Tel. +43 7435 58193 0
Commercial register no.: FN 435233z, Handelsgericht St. Poelten
VAT no.: ATU69753849

Meet us

Meet us next... the European Students Conference ( in Berlin. Cube Dx presents its Integrated Sepsis Diagnostics during a focussed industry exhibition and seminar on 29th of September, 2016. Make sure to be there. If you want to meet, make an appointment using!

News Ticker

Latest News...

We believe that the simultaneous (and parallel) measurement and evaluation of a set of biomarkers could improve the quality of clinical decisions of sepsis treatment. At ANESTHESIOLOGY® 2015, organised by the American Society of Anesthesiologists, a first study dealing with the quality of prognosis for single inflammatory and kidney markers in comparison to a combination of two of these markers was presented. The study was carried out by the Clinics of the Ludwig-Maximilians-University, Munich in collaboration with Clinic Neuperlach of the Municipal Hospital Munich.

The authors conclude that a combination of an inflammatory and a kidney biomarker leads to a significantly better prognosis than the use of single biomarkers, and can therefore more readily identify patients that are most critically affected by the disease. The authors recommend the simultaneous measurement of biomarkers to stratify a patient’s risk to die or of suffering critical kidney failure.